Year None20232022202120202019201820172016 01-23-2023 Pliant Therapeutics Announces Proposed Public Offering of Common Stock 01-22-2023 Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis 01-03-2023 Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference Pagination First page « first Previous page ‹ previous Page 1 Current page 2
